罗格列酮对2型糖尿病患者尿白蛋白的影响  

Effects of rosiglitazone on urinary albumin in type 2 diabetic patients

作　　者：高贤荣[1] 杜瑞伶[1] 马美英[2] 

机构地区：[1]北京市顺义区医院内分泌科,101300 [2]北京市顺义区医院肾内科,101300

出　　处：《中国实用医药》2010年第23期20-21,共2页China Practical Medicine

摘　　要：目的探讨罗格列酮对2型糖尿病早期肾病的临床疗效。方法将2型糖尿病早期肾病患者80例随机分为常规治疗组(40例)、罗格列酮治疗组(40例),另选36名单纯糖尿病患者作对照,测定尿白蛋白排泄率(UAER)、同型半胱氨酸(Hcy)及胰岛素抵抗指数(HOMA-IR)等。结果罗格列酮组UAER,Hcy及HOMA-IR、TC、HDL-C均较治疗前显著改善(P<0.01或P<0.05),常规治疗组治疗前后上述结果无明显变化(均P>0.05)。结论 RGZ可改善IR,调节血脂,同时可降低尿白蛋白排泄率,对早期糖尿病肾病有保护作用。Objective To evaluate the efficacy of rosiglitazone in treating early diabetic nephropathy （ DN） patients. Methods Patients with early DN were randomly divided into two groups：routine treat group,rosiglitazone treat group,and contrast with simple diabetes mellitus patients. Levels of HOMA-IR,UAER,Hcy were detected. Results In rosiglitazone treat group UAER,Hcy,Fins,HOMA-IR were markedly decreased （ P 0. 01）. UAER,Hcy,Fins,HOMA-IR did not show any significant change in routine treat group （ P 0. 05）. Conclusion Rosiglitazone relieves insulin resistance,and decreases urine albumin excretion in early diabetic nephropathy.

关 键 词：罗格列酮 糖尿病肾病 微量白蛋白尿 同型半胱氨酸 

分 类 号：R587.1[医药卫生—内分泌]